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Communication between endothelial and smooth muscle cells (SMCs) contributes to atherosclerosis
induced by atherogenic factors, such as oxide LDL. Asymmetric dimethylarginine (ADMA), a newly
found cardiovascular risk factor, accumulates in the culture medium of oxide LDL (oxLDL)-treated
endothelial cells and positively correlates with atherosclerosis. This study demonstrates that ADMA
mediates the communication between endothelial cells and SMCs induced by oxLDL leading to SMC
migration. In addition, the present study suggests exogenous ADMA directly induces SMC migration
via p38 and ERK1/2 MAPK signaling transduction way. Investigations to identify the factors regulat-
ing VSMC migration may provide novel insights into atherosclerosis and its complications.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis and its complications, including myocardial
infarction, stroke, and peripheral vascular disease, remain a major
cause of death in industrialized countries [1]. Vascular smooth
muscle cell (VSMC) migration plays a critical role in the initiation
and progression of intimal thickening in atherosclerotic lesions
[2]. Interactions between endothelial cells and VSMCs are involved
in both normal functions of the vessel wall and the development of
atherosclerosis. In this context, communication between endothe-
lial cells and VSMCs has to be taken into account when investigat-
ing the migration of VSMCs into the arterial wall.
Oxidized low-density lipoprotein (oxLDL) contributes to VSMC
migration; however, the mechanisms responsible for the effects
of oxLDL on VSMCmigration are not yet fully understood. Recently,
asymmetric dimethylarginine (ADMA), an endogenous inhibitor of
nitric oxide synthase (NOS) and a newly found cardiovascular riskchemical Societies. Published by E
rmaceutical Screening, Insti-
al Sciences & Peking Union
g 100050, China. Fax: +86
05@gmail.com (G. Du).factor, was reported to accumulate in the culture medium of
oxLDL-treated endothelial cells [3]. However, whether ADMA
mediates the communication between endothelial and smooth
muscle cells leading to VSMC migration remains uncertain.
We hypothesized that ADMA mediates the communication be-
tween endothelial and smooth muscle cells that is triggered by
oxLDL and leads to VSMC migration. In addition, since ADMA in-
duces mitogen-activated protein kinases (MAPKs), including extra-
cellular signal-regulated kinase1/2 (ERK1/2), c-Jun NH2-terminal
kinase (JNK), and p38MAPK, which are a family of central signaling
molecules that respond to numerous stimuli in vascular smooth
muscle cells [4], we also hypothesized that the impact of ADMA
on VSMC migration would be partly due to ADMA-induced activa-
tion of MAPK signal transduction.
Investigations to identify factors regulatingVSMCmigrationmay
provide novel insights into atherosclerosis and its complications.2. Materials and methods
2.1. Antibodies and major reagents
See Supplementary material.lsevier B.V. All rights reserved.
Fig. 1. HUVEC-conditioned medium pretreated with oxLDL induces VSMC migration. HUVECs were pretreated with oxLDL at different concentrations (0, 20, 40, 60, and
80 lg/ml) for 12 h. Native LDL was used as a control. The supernatant was collected and used as conditioned medium. In the Transwell migration assay, VSMCs were seeded in
the upper chamber of the Transwell and the conditioned medium was supplemented in the bottom chamber. The growth medium was DMEM (without L-arginine) containing
5 mM hydroxyurea to prevent HUVEC and VSMC proliferation. Twelve hours later, cells that migrated through the 8 lm pores were stained with 40 ,6-diamidino-2-
phenylindole  2HCl (DAPI). The number of VSMCs that migrated onto the lower surface of each ﬁlter was counted in different ﬁelds at a magniﬁcation of 200 by three
independent observers with Image Pro Plus 5.0 software (Media Cybernetics, GA, US). (A–B) DDAH2 protein and mRNA expression level in HUVECs. (C) ADMA concentration
in the conditioned medium of HUVECs. D: Representative images of VSMCs that migrated through the pores of a Transwell chamber. Images 1–5 are representative of
treatment with HUVEC-conditioned medium pretreated with oxLDL or LDL at the concentrations of 0, 20, 40, 60, and 80 lg/ml, respectively. E: The correlation between ADMA
concentration in the conditioned medium and the number of migrated VSMCs. Data, expressed as mean ± S.E.M., are representative of at least three independent experiments.
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Fig. 2. DDAH2 knock-down enhances the oxLDL-mediated induction of VSMC migration. The following siRNAs were generated against the human DDAH2 mRNA sequence:
siRNA-1, 50-UGCUGACAGAUCACCCAUATT-30; siRNA-2, 50-GCUCCGAAUUGUGGAAAUATT-30; siRNA-3, 50-GAUCUGGCCAAAGCUCAAATT-30; and siRNA-4, 50-GCUGACAGAU-
CACCCAUAUTT-30 . As controls, a scrambled siRNA and negative control siRNA not exhibiting homology to any coding region of DDAH2 were used. The FAM labeled negative
control siRNA was used for transfection control. Subsequently, siRNA-1 was selected for further use. After being transfected with siRNA-1 or scrambled siRNA for 24 h,
HUVECs were treated with oxLDL (60 lg/ml). The growth medium was DMEM (without L-arginine) containing 5 mM hydroxyurea to prevent HUVEC proliferation. (A) DDAH2
protein and mRNA expression levels in HUVECs transfected with different siRNAs. (B) DDAH2 protein and mRNA expression level in different (Transfected with DDAH2 siRNA
or not) treated with or without oxLDL (60 lg/ml). (C) ADMA concentration in HUVEC-conditioned medium. (D) Number of VSMCs that migrated through the pores of a
Transwell chamber after treatment with HUVEC-conditioned medium. (E–H) Representative images of VSMCs that migrated after stimulation with different HUVEC-
conditioned medium. Data are expressed as mean ± S.E.M. and are representative of at least three independent experiments.
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Fig. 3. Overexpression of DDAH2 in HUVECs prevented the induction of VSMC migration by HUVEC-conditioned medium. hDDAH2 expression vector or the empty EGFP
vector were transiently transfected into HUVECs, and the HUVECs were treated with oxLDL (60 lg/ml). (A) DDAH2 protein expression level in HUVECs pretreated with
different transfections. (B) DDAH2 protein and mRNA expression levels in HUVECs treated with or without oxLDL. (C) ADMA concentration in HUVEC-conditioned medium.
(D–H) Number of migrated VSMCs and representative images of VSMCs in Transwell assay after treatment with HUVEC-conditioned medium. Data are expressed as
mean ± S.E.M. and are representative of at least three independent experiments.
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Fig. 4. Exogenous ADMA induces VSMC migration. Conﬂuent VSMCs (starved for 48 h in FCS-free DMEM) were treated with ADMA at different concentrations (0–30 lM) for
24 h. The migration activity was expressed as the change in covered area. (A–E) VSMC migration induced by 0, 1, 3, 10, and 30 lM ADMA for 24 h, respectively. The upper,
middle, and bottom images represent the beginning point, end point, and merged images, respectively. The red shadow represents the change in covered area. Samples were
run in triplicate in three independent experiments. (F) Change in covered area.
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LDL was isolated from healthy blood as previously described [5]
and oxidation of LDL was performed by dialyzing against 10 lM
CuSO4 in PBS for 24 h at 37 C as described [6]. (Detailed protocol
was included in Supplementary material.)
2.3. Cell culture
See Supplementary material.
2.4. DDAH2 overexpression and knock-down
ADMA is hydrolyzed to L-citrulline and dimethylamine by
dimethylarginine dimethylaminohydrolase 2 (DDAH2) in the car-
diovascular system. The strategies of DDAH2 overexpression and
knock-down were used to modulate the level of ADMA. The proto-
col was attached in the Supplementary material.
2.5. VSMC migration assay
Tanswell Assay was used to evaluate VSMC migrating ability
[7]. Detailed protocol was enclosed in Supplementary material.
2.6. Wound-healing assay
Cell migration was also assessed using wound-healing assays as
previous described [8]. The migration/growth medium was DMEM
without L-arginine containing 5 mM hydroxyurea to prevent VSMC
proliferation. Four different ﬁelds of migration were photographed
with a video camera system using Image Pro Plus 5.1 software at
the intersection of the previously marked line and wound edgebefore and after treatment with ADMA. The migration activity
was expressed as the change in covered area.
2.7. Western blotting
Immunoprecipitation and immunoblotting were performed as
previously described [9].
2.8. Determination of ADMA concentration
The level of ADMA in the conditionedmediumwas measured by
ELISA (DLD Diagnostika, Germany). Detailed protocol was included
in Supplemental material.
2.9. Statistical analysis
Data are expressed as mean + S.E.M. Each experiment was
repeated three times, and representative results are shown. The
Kolmogorov–Smirnov method was used to test the normal distri-
bution [10]. One-way ANOVA was used to analyze values, fol-
lowed by Student’s t-tests to distinguish signiﬁcant differences.
A P-value < 0.05 was considered signiﬁcant.
3. Results and discussion
3.1. oxLDL induces ADMA accumulation in HUVEC-conditioned
medium via the inhibition of DDAH2 activity and expression
In agreement with previous studies [11], the results presented
here show that oxLDL markedly increased ADMA accumulation
via the inhibition of DDAH2 activity and the reduction of DDAH2
expression (Fig. 1A and B) in HUVECs.
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nohydrolase in the cardiovascular system, is the speciﬁc hydrolase
of ADMA andmodulates ADMA levels. DDAH2 activity ismodulated
at the post-translational and transcriptional levels, which be di-
rectly inactivated by various oxidative or inﬂammatory stimuli.
The expression level can also be down-regulated by lipopolysaccha-
ride (LPS) or high glucose [12]. In this study, the concentrations of
oxLDL required to have an effect on DDAH2 activity and DDAH2
expression are different. oxLDL treatment between 20 and 80 lg/
ml led to a signiﬁcant decrease in DDAH2 activity that was repre-
sented by the accumulation of ADMA (Fig. 1C). When HUVECs were
treated with oxLDL at a concentration exceeding 60 lg/ml, the
expression of DDAH2 at both the mRNA and protein levels was
markedly decreased (Fig. 1A and B). Thus, oxLDL induces ADMA
accumulation in HUVEC-conditioned medium via the inhibition of
DDAH2 activity and expression.
3.2. ADMA facilitates communication between HUVECs and VSMCs
and leads to VSMC migration
Cell communication can occur via soluble mediators. Mediators
secreted by endothelial cells can lead to VSMC migration, collagen
synthesis, VSMC phenotype change, and secretion of hyaluronicFig. 5. DDAH2 blunts the inducing effects of ADMA on VSMC migration. VSMCs transfect
ADMA (10 lM) for 24 h. All transfections were carried out in triplicate, and each experim
change in covered area. (A) DDAH2 expression level in VSMCs with different transfection
images represent the beginning point, end point, and merged images, respectively. Theacid. In previous studies [13,14], ADMA was induced by Hcy and
Ang II in endothelial cells and led to the apoptosis of VSMC. In this
study, the conditioned medium from oxLDL-treated HUVECs mark-
edly increased the number of VSMCs that migrated through the
Transwell chamber (Fig. 1D and E), indicating that a soluble factor
was generated in endothelial cells and secreted into the medium.
Considering the accumulation of ADMA in the conditioned med-
ium, we proposed that ADMA was the critical mediator that in-
duced VSMC migration. In fact, the positive correlation between
ADMA concentration in the medium and the number of migrated
VSMC supports the conclusion that ADMA is an interaction factor
between endothelial cells and VSMCs (correlation coefﬁ-
cient = 0.8724628, P < 0.01, Fig. 1F).
To further conﬁrm the role of the DDAH2/ADMA pathway, the
strategies of DDAH2 knock-down and overexpression were applied.
Transfection of HUVECs with DDAH2 siRNA successfully knocked
down DDAH2 expression at both the mRNA and protein levels in
oxLDL-treated and untreated HUVECs (Fig. 2A and B). In contrast,
scramble siRNA, not targeting any known cDNA, did not affect
DDAH2 expression. Our results showed that the effect of oxLDL
on the accumulation of ADMA in HUVEC medium was ampliﬁed
by DDAH2 knock-down (Fig. 2C) and the inducing effects of
HUVEC-conditioned medium on VSMC migration was signiﬁcantlyed with the hDDAH2 expression vector or the empty EGFP vector were treated with
ent was reproduced four to six times. The migration activity was expressed as the
s. (B–F) VSMC migration with different treatments. The upper, middle, and bottom
red shadow represents the change in covered area. (F) Change in covered area.
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number of migrated cells (Fig. 2D–H).
We constructed a human DDAH2 expression vector and tran-
siently transfected it into HUVECs (Fig. 3A and B). DDAH2 overex-
pression in HUVECs blunted the accumulation of ADMA in the
conditioned medium (Fig. 3C) and reduced the number of VSMCs
that migrated (Fig. 3D–I). The empty pIRES2-EGFP vector did not
inﬂuence ADMA generation or VSMC migration.
Our results indicate that overexpression of DDAH2 signiﬁcantly
blunted the accumulation of ADMA in the conditioned medium
and reduced the number of migrated VSMCs. On the contrary,
knock-down of DDAH2 enhanced the elevation of ADMA in the
supernatant and increased the number of migrated VSMCs. Our re-
sults demonstrate that ADMA facilitates the communication be-
tween endothelial and smooth muscle cells and ﬁnally leads to
VSMC migration. This study is the ﬁrst to report the role that the
DDAH2/ADMA pathway plays in oxLDL-induced VSMC migration.
3.3. Exogenous ADMA directly induces VSMC migration
To further conﬁrm the contribution of ADMA in the process of
oxLDL-induced VSMC migration, the effect of exogenous ADMA
was observed in wild-type and hDDAH2-overexpressing VSMCs.
ADMA induced VSMC migration in a concentration-dependent
manner in the concentration range of 3–30 lM, as assessed by
the conﬂuent area of VSMCs in a wound-healing assay (Fig. 4A–
E). According to the previously reported highest plasma ADMA lev-
els in patients with different clinical conditions [15] and in exper-
imental atherosclerotic animals [16,17] and the popularly used
ADMA concentrations for in vitro studies, 10 lM ADMA was se-
lected for further investigation in this study.
Then the same concentrations of symmetric dimethylarginine
(SDMA), an ADMA analogue, were used as controls in order to
investigate whether the inducing effects on VSMC migration were
ADMA-speciﬁc. Treatment of VSMCs with 10 lM ADMA increased
VSMC migration 2.9-fold (Fig. 4I and L, P < 0.01), while SDMA did
not (Fig. 4H and L, P > 0.05), indicating that the effect on VSMC is
ADMA-speciﬁc. To distinguish whether the effects of ADMA on
VSMC migration is NO-dependent, we used DMEM (without L-argi-
nine) as the growth medium [18]. Therefore, the effect of ADMA on
VSMC migration is NO-independent. It is interesting that the pre-
cursor of NO, L-arginine, markedly blocked ADMA-induced VSMC
migration (Fig. 4J–L), indicating that supplemental NO donors can
partly blunt the pathological effects of ADMA on VSMC. Because
ADMA is a speciﬁc substrate of DDAH2, transient transfection of
the hDDAH2 expression vector into VSMCs (Fig. 5A) signiﬁcantly
attenuated the migration induced by exogenous ADMA (Fig. 5B–
G). Our results conﬁrmed that the DDAH2/ADMA pathway plays
an important role in VSMC migration.
Pretreatment with L-arginine and overexpression of hDDAH2
attenuated the activation of VSMC migration induced by ADMA,
suggesting that supplemental NO donors or acceleration of ADMA
degradation can blunt the pathological effect of ADMA on VSMCs.
This is in agreementwith previous studies [19–21]. ADMAmediates
multiple pathological effects, including apoptosis, oxidative and
nitrodative stress, proliferation, and pro-inﬂammation in VSMCs
[22–24]. Our demonstration of the effect of ADMA on VSMC migra-
tion may have implications on future studies of artherosclerosis.
The effect of DDAH2 overexpression or L-arginine on VSMC migra-
tion indicates potential therapeutic strategies for artherosclerosis.
3.4. ADMA induces VSMC migration via the p38MAPK and ERK1/2
signal transduction pathways
VSMC migration may be involved in multiple signaling path-
ways [25]. MAPKs, ERK1/2, JNK, and p38MAPK, are a family ofcentral signaling molecules that respond to numerous stimuli
and participate in cell proliferation and migration [26]. Activation
of JNK, p38MAPK, and ERK1/2 induces migration, and inhibition
of JNK, p38MAPK, and ERK1/2 protects VSMCs against migration
[26,27].
In this study, ADMA signiﬁcantly activated the ERK1/2 and
p38MAPK signaling transduction pathways, but not the JNK signal
transduction pathway in VSMCs (Supplementary Fig. 1). To deter-
mine whether the ERK1/2 and p38MAPK pathways were involved
in ADMA-induced migration of VSMCs, PD98059 (ERK1/2-speciﬁc
inhibitor) and SB203580 (p38MAPK-speciﬁc inhibitor) were used.
Pretreatment with speciﬁc inhibitor of p38MAPK and ERK1/2
(SB203580 and PD98059) signiﬁcantly inhibited phosphorylation
of p38MAPK and ERK1/2 (Supplementary Fig. 2) and attenuated
ADMA-induced cell migration (Supplementary Fig. 3), indicating
that their activation contributed to ADMA-induced migration of
VSMCs.
4. Conclusion
In conclusion, oxLDL induces the accumulation of the soluble
factor ADMA in HUVECs via the inhibition of DDAH2 activity and
expression, thereby inducing VSMC migration. Also, ADMA induces
VSMC migration via the p38MAPK and ERK1/2 signal transduction
pathways. To the best of our knowledge, this is the ﬁrst study to
demonstrate cell communication facilitated by ADMA that leads
to VSMC migration. We hope that this study contributes novel in-
sights regarding potential therapy for and prevention of athero-
sclerosis and its complications.
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